Showing results (31-40 of 43) with videos related to

Sort By:
Pageof 5
EJNMMI Radiopharmacy and Chemistry|November 22, 2023
Optimized, automated and cGMP-compliant synthesis of the HER2 targeting [68Ga]Ga-ABY-025 tracerEmma Jussing, Mélodie Ferrat, Mohammad M Moein, et al.
Journal of Nuclear Medicine Technology|April 16, 2024
Acquisition Duration Optimization Using Visual Grading Regression in [68Ga]FAPI-46 PET Imaging of Oncologic PatientsTed Nilsson, Pawel Rasinski, Örjan Smedby, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|January 29, 2026
Feasibility of [89Zr]Zr-Atezolizumab Immuno-PET for PD-L1 Quantification in the Clinical Work-up of Metastatic Triple-Negative Breast CancerJoni J Nijveldt, Siri Af Burén, Thuy A Tran, et al.
Nuclear Medicine and Biology|January 12, 2015
Radiolabeled antibodies in prostate cancer: a case study showing the effect of host immunity on antibody bio-distributionOskar Vilhelmsson-Timmermand, Elmer Santos, Daniel L J Thorek, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|April 18, 2009
Targeting of HER2-expressing tumors with a site-specifically 99mTc-labeled recombinant affibody molecule, ZHER2:2395, with C-terminally engineered cysteineSara Ahlgren, Helena Wållberg, Thuy A Tran, et al.
International Journal of Nanomedicine|September 5, 2020
Molecular Imaging of Inflammation in a Mouse Model of Atherosclerosis Using a Zirconium-89-Labeled ProbeMona Ahmed, Tetyana Tegnebratt, Thuy A Tran, et al.
EJNMMI Research|August 8, 2023
Comparative in vivo biodistribution of cells labelled with [89Zr]Zr-(oxinate)4 or [89Zr]Zr-DFO-NCS using PETIda Friberger, Joachim N Nilsson, Li Lu, et al.
Scientific Reports|July 8, 2017
Combined Magnetomotive ultrasound, PET/CT, and MR imaging of 68Ga-labelled superparamagnetic iron oxide nanoparticles in rat sentinel lymph nodes in vivoMaria Evertsson, Pontus Kjellman, Magnus Cinthio, et al.
Molecular Imaging and Biology|July 7, 2021
Optimisation of the Synthesis and Cell Labelling Conditions for [89Zr]Zr-oxine and [89Zr]Zr-DFO-NCS: a Direct In Vitro Comparison in Cell Types with Distinct Therapeutic ApplicationsIda Friberger, Emma Jussing, Jinming Han, et al.
Theranostics|June 1, 2019
Preclinical efficacy of hK2 targeted [177Lu]hu11B6 for prostate cancer theranosticsOskar Vilhelmsson Timmermand, Jörgen Elgqvist, Kai A Beattie, et al.
Pageof 5